MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences.
Indianapolis startup ImmuneWorks is developing drugs to treat lung transplant patients, idiopathic pulmonary fibrosis and other fibrotic lung diseases.
The 8-year-old company was founded by two researchers at the Indiana University School of Medicine – Dr. David Wilkes and Michael Klemsz.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
ImmuneWorks is building off the idea that autoimmunity against Type 5 Collagen is a significant contributor to idiopathic pulmonary fibrosis and lung transplant rejection. The company says it’s translating these findings into drug development by applying mucosal tolerance to alter the immune response against this form of collage. By extension, it alters the immune response against Type 5 Collagen and thereby halts the progression of fibrosis in these diseases.
The company just finished a Phase 1 clinical trial of its lead asset, IW001, in subjects with idiopathic pulmonary disease. The results of this trial should bring it solidly into Phase 2’s –
The company has raised a little over $12 million since its genesis, and hopes to generate another $14 million in financing.
